Highly proliferating tumours, such as malignant thymic and bronchial carcinoids, derive the maximum benefit; midgut tumours with low proliferation (Ki67 antibody < 2%) may not benefit from cytotoxic therapy. Here, MKI67 is linked to neoplasm.